Advances in hepatitis C therapies.
The recent development of new direct acting antivirals constitutes a clinical revolution in the field of hepatitis C therapy. Different drugs with direct antiviral effects and very high potency have been developed, changing the current scenario and prognosis of hepatitis C-related liver disease. This review aims to clarify the current stage of the different antiviral strategies in patients with chronic hepatitis C infection by analyzing the specific efficacy of each combination. Data have been extracted from the most important published clinical trials, cumulative real-world experience reports and data from the most relevant studies presented in the last international meetings (European and American International Liver Congresses). In addition, data from the recently updated international guidelines have also been included. Although there are many differences in health-care budgets among countries in the world which will surely compromise drug availability and treatment decisions, this review aims to give a general and brief recommendation to help treating physicians to choose the best option to treat hepatitis C.